Thyroid hormone receptor β1 domains responsible for the antagonism with the ras oncogene: role of corepressors.

Department of Endocrine and Nervous System Physiopathology, Instituto de Investigaciones Biomedicas, Consejo Superior de Investigaciones Cientificas and Universidad Autonoma de Madrid, Madrid, Spain.
The thyroid hormone receptor (TR) is a suppressor of ras-mediated responses. To characterize the receptor domains involved in this function, we analyzed a panel of TRβ1 mutants for their ability to interfere with ras-driven cyclin D1 activation, formation of transformation foci and tumor growth in nude mice. Our results show that the domains and mechanisms responsible for the anti-transforming and anti-tumorigenic actions of the receptor are divergent from those operating in classical T3-dependent transcriptional activation. TRβ1 mutants that do not bind coactivators and do not transactivate retained the capacity of suppressing cellular transformation and tumor growth, whereas selective mutations in the hinge region affecting corepressors recruitment abolished these actions, while preserving ligand-dependent transcription. There was a strict parallelism between anti-transforming activity of the various mutants and their ability to antagonize cyclin D1 stimulation by ras, indicating that transrepression mechanisms may have an important function in suppression of the transforming effects of the oncogene by TRβ1. The inhibitory action of T3 on transformation was further enhanced after over-expression of corepressors, while corepressor depletion by means of small-interference RNA reversed significantly hormonal action. This shows an important functional role of endogenous corepressors in suppression of ras-mediated transformation and tumorigenesis by TRβ1.
Mesh Terms:
Animals, Cell Transformation, Neoplastic, Co-Repressor Proteins, Cyclin D1, Genes, ras, Hep G2 Cells, Humans, Mice, Mice, Nude, Mutation, Protein Interaction Domains and Motifs, RNA, Small Interfering, Thyroid Hormone Receptors beta, Triiodothyronine
Oncogene Feb. 17, 2011; 30(7);854-64 [PUBMED:20956942]
Download 2 Interactions For This Publication
149512
Switch View:
  • Interactions (2)